The Role of Artificial Intelligence in Drug Discovery and Pharmaceutical Development: A Paradigm Shift in the History of Pharmaceutical Industries
- PMID: 40360908
- DOI: 10.1208/s12249-025-03134-3
The Role of Artificial Intelligence in Drug Discovery and Pharmaceutical Development: A Paradigm Shift in the History of Pharmaceutical Industries
Abstract
In today's world, with an increasing patient population, the need for medications is increasing rapidly. However, the current practice of drug development is time-consuming and requires a lot of investment by the pharmaceutical industries. Currently, it takes around 8-10 years and $3 billion of investment to develop a medication. Pharmaceutical industries and regulatory authorities are continuing to adopt new technologies to improve the efficiency of the drug development process. However, over the decades the pharmaceutical industries were not able to accelerate the drug development process. The pandemic (COVID-19) has taught the pharmaceutical industries and regulatory agencies an expensive lesson showing the need for emergency preparedness by accelerating the drug development process. Over the last few years, the pharmaceutical industries have been collaborating with artificial intelligence (AI) companies to develop algorithms and models that can be implemented at various stages of the drug development process to improve efficiency and reduce the developmental timelines significantly. In recent years, AI-screened drug candidates have entered clinical testing in human subjects which shows the interest of pharmaceutical companies and regulatory agencies. End-end integration of AI within the drug development process will benefit the industries for predicting the pharmacokinetic and pharmacodynamic profiles, toxicity, acceleration of clinical trials, study design, virtual monitoring of subjects, optimization of manufacturing process, analyzing and real-time monitoring of product quality, and regulatory preparedness. This review article discusses in detail the role of AI in various avenues of the pharmaceutical drug development process, its limitations, regulatory and future perspectives.
Keywords: artificial intelligence; deep learning; drug development; drug discovery; machine learning.
© 2025. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no conflict of interests.
Similar articles
-
Recent Development, Applications, and Patents of Artificial Intelligence in Drug Design and Development.Curr Drug Discov Technol. 2025;22(4):e15701638364199. doi: 10.2174/0115701638364199250123062248. Curr Drug Discov Technol. 2025. PMID: 39931986 Review.
-
AI in Clinical Trials and Drug Development: Challenges and Potential Advancements.Curr Drug Discov Technol. 2025;22(4):e15701638314252. doi: 10.2174/0115701638314252241016165345. Curr Drug Discov Technol. 2025. PMID: 39473260 Review.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3. PMID: 29271481 Free PMC article. Updated.
-
Application of artificial intelligence in drug design: A review.Comput Biol Med. 2024 Sep;179:108810. doi: 10.1016/j.compbiomed.2024.108810. Epub 2024 Jul 10. Comput Biol Med. 2024. PMID: 38991316 Review.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
References
-
- Zhavoronkov A, Ivanenkov YA, Aliper A, Veselov MS, Aladinskiy VA, Aladinskaya AV, Terentiev VA, Polykovskiy DA, Kuznetsov MD, Asadulaev A, et al. Deep Learning Enables Rapid Identification of Potent DDR1 Kinase Inhibitors. Nat Biotechnol. 2019;37:1038–40. https://doi.org/10.1038/s41587-019-0224-x . - DOI - PubMed
-
- Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Žídek A, Potapenko A, et al. Highly Accurate Protein Structure Prediction with AlphaFold. Nature. 2021;596:583–9. https://doi.org/10.1038/s41586-021-03819-2 . - DOI - PubMed - PMC
-
- Bereczki Z, Benczik B, Balogh OM, Marton S, Puhl E, Pétervári M, Váczy-Földi M, Tamas Papp Z, Papp T, Makkos A, et al. Mitigating Off-target Effects of Small RNAs: Conventional Approaches, Network Theory and Artificial Intelligence. Br J Pharmacol. 2024;182:340–79. https://doi.org/10.1111/bph.17302 . - DOI - PubMed
-
- Jyoti Verma, G. Unleashing the Power of Artificial Intelligence: Exploring Multidisciplinary Frontiers for Innovation and Impact. In Artificial Intelligence for Intelligent Systems; Inam, U.K., Ed.; Taylor & Francis Group, 2024. ISBN 9781003496410.
-
- Mazumdar H, Khondakar KR, Das S, Halder A, Kaushik A. Artificial Intelligence for Personalized Nanomedicine; from Material Selection to Patient Outcomes. Expert Opin Drug Deliv 2024;85–100. https://doi.org/10.1080/17425247.2024.2440618 .
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources